Aptose Biosciences, Inc.

📍 San Diego, United States🗓 Founded 2014👥 42 employees💰 Last funded Dec 2014
Biotechnology Research🌐 aptose.com
Website LinkedIn
Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies. CG-806, our oral mutation-agnostic FLT3/BTK inhibitor, is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments. CG-806 is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies. APTO-253, our first-in-class MYC Inhibitor, is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2014
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Switzerland
1
Canada
1
Frequently asked questions
Who invested in Aptose Biosciences, Inc.?
Aptose Biosciences, Inc. has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Aptose Biosciences, Inc. last raise funding?
The most recent investment in Aptose Biosciences, Inc. recorded on gritt.io was in December 2014.
When was Aptose Biosciences, Inc. founded?
Aptose Biosciences, Inc. was founded in 2014.
What industry is Aptose Biosciences, Inc. in?
Aptose Biosciences, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Aptose Biosciences, Inc. based?
Aptose Biosciences, Inc. is headquartered in San Diego, United States.